tiprankstipranks
Trending News
More News >
Shanghai Kindly Medical Instruments Co., Ltd. Class H (HK:1501)
:1501
Hong Kong Market

Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) AI Stock Analysis

Compare
2 Followers

Top Page

HK

Shanghai Kindly Medical Instruments Co., Ltd. Class H

(1501)

Rating:66Neutral
Price Target:
Shanghai Kindly Medical Instruments Co., Ltd. Class H's stock score is driven primarily by its strong financial performance, highlighted by robust revenue growth and a solid balance sheet. Despite these strengths, technical analysis reveals weak momentum and bearish trends, while valuation metrics suggest the stock is fairly valued, limiting potential for significant upside. Cash flow challenges remain a concern, impacting the overall score.

Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) vs. iShares MSCI Hong Kong ETF (EWH)

Shanghai Kindly Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company DescriptionShanghai Kindly Medical Instruments Co., Ltd. engages in the research and development, manufacture, and sale of cardiovascular interventional medical devices in Mainland China, Europe, the United States, and internationally. The company offers interventions products, which includes guiding catheter used to provide a channel for introducing balloon catheter, guidewire or other treatment devices; micro catheter to support the placement of guide wires; guidewire used in percutaneous transluminal angioplasty (PTA) surgical procedures; angiography catheter used to inject and infuse contrast media and fluid; and Y-connector pack used in PTCA surgery. It also provides inflation device used to inflate the balloon of dilating the vessel or placing the stent in the vessel; manifold for single use; manifold kit; pressure bandage used to assist compression hemostasis; angiography syringe for single use; stopcocks used for pressure monitoring tubing during surgery; sterile seldinger needle used to puncture into the artery; introducer set; pressure transducer for single use; extension tube for pressure monitoring; and introducer tool kit used in percutaneous vertebroplasty. In addition, the company offers medical accessories, such as check value, needle free connector, male Luer locks, bi-stopper, Heparian cap, flush device, and flow regulator; other products, including joint intervention kit, disposable respirator masks, vaginal dilator used during a vaginal examination, foley catheter, infusion pumps, disposable automatic umbilical cord clamps, infusion connector and accessory for single use, and burette infusion sets without a needle. It serves medical device manufacturers and other customers. The company was founded in 2006 and is headquartered in Shanghai, China. Shanghai Kindly Medical Instruments Co., Ltd. is a subsidiary of Shanghai Kindly Enterprise Development Group Co., Ltd.
How the Company Makes MoneyShanghai Kindly Medical Instruments Co., Ltd. generates revenue through the sale of its diverse range of medical devices to hospitals, clinics, and healthcare providers both domestically and internationally. The company's key revenue streams include direct sales of its products to medical institutions and partnerships with distributors who facilitate the broader reach of its products in different regions. Additionally, the company invests in research and development to innovate and expand its product offerings, which helps maintain its competitive edge and supports sustained revenue growth. Strategic collaborations with other medical technology firms and participation in healthcare exhibitions also contribute to its market presence and earnings.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary
Shanghai Kindly Medical Instruments Co., Ltd. Class H demonstrates strong financial performance with robust revenue growth and high profitability margins. The balance sheet is solid with low leverage, reducing financial risk. However, cash flow shows room for improvement, reflecting potential challenges in cash generation from operations.
Income Statement
85
Very Positive
Shanghai Kindly Medical Instruments Co., Ltd. Class H has demonstrated strong income statement performance with a consistent upward trajectory in revenue growth, showing an impressive revenue growth rate from 2023 to 2024 at 13.15%. Gross profit margin remains robust at approximately 63.11%, indicating effective cost management. The net profit margin also improved, reaching 22.53% in 2024, reflecting enhanced profitability. The company maintains healthy EBIT and EBITDA margins at 25.38% and 29.98%, respectively, showcasing operational efficiency. The key strength lies in sustained revenue growth and high profitability margins, although the company should monitor any future fluctuations in margins.
Balance Sheet
88
Very Positive
The balance sheet of Shanghai Kindly Medical Instruments Co., Ltd. Class H reveals a strong financial position with an equity ratio of 78.51% in 2024, indicating a solid equity base relative to total assets. The debt-to-equity ratio remains low at 0.14, suggesting minimal leverage and reduced financial risk. Return on equity improved to 10.82%, reflecting enhanced returns for shareholders. The company benefits from a strong equity position and low leverage, which contributes to financial stability and mitigates risk.
Cash Flow
70
Positive
Cash flow analysis for Shanghai Kindly Medical Instruments Co., Ltd. Class H shows areas for improvement. The operating cash flow to net income ratio is low due to operating cash flow being unavailable in 2024. Free cash flow remains a concern with fluctuations observed in prior years, indicating potential challenges in cash generation from operations. However, the company has managed to maintain a positive free cash flow in earlier periods, suggesting potential for recovery in cash flow generation. Focus should be placed on enhancing cash flow efficiency.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
851.95M752.84M585.88M464.68M358.43M
Gross Profit
537.66M438.07M332.49M275.75M234.41M
EBIT
216.21M178.32M129.34M144.64M125.35M
EBITDA
255.43M225.88M159.99M168.81M143.23M
Net Income Common Stockholders
191.91M156.46M131.71M142.96M121.35M
Balance SheetCash, Cash Equivalents and Short-Term Investments
554.51M434.40M528.27M640.55M941.59M
Total Assets
2.26B2.03B1.83B1.62B1.42B
Total Debt
243.69M94.78M48.83M13.40M1.73M
Net Debt
-278.27M-328.89M-469.44M-627.15M-868.40M
Total Liabilities
473.39M351.25M273.23M183.63M95.04M
Stockholders Equity
1.77B1.65B1.51B1.40B1.31B
Cash FlowFree Cash Flow
59.80M-53.05M-62.75M-205.07M7.92M
Operating Cash Flow
225.54M178.15M180.46M72.76M95.71M
Investing Cash Flow
-187.31M-283.81M-316.18M-268.08M-221.87M
Financing Cash Flow
56.97M8.06M9.72M-31.07M-27.95M

Shanghai Kindly Medical Instruments Co., Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Negative
Last Price25.70
Price Trends
50DMA
26.34
Negative
100DMA
26.87
Negative
200DMA
27.55
Negative
Market Momentum
MACD
-0.33
Negative
RSI
42.47
Neutral
STOCH
79.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1501, the sentiment is Negative. The current price of 25.7 is above the 20-day moving average (MA) of 25.55, below the 50-day MA of 26.34, and below the 200-day MA of 27.55, indicating a bearish trend. The MACD of -0.33 indicates Negative momentum. The RSI at 42.47 is Neutral, neither overbought nor oversold. The STOCH value of 79.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1501.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
HK$4.52B20.3211.24%1.17%11.23%20.39%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
$4.20B11.8714.56%5.03%
HK$298.29M
$7.42B6.959.19%5.60%
$3.30B11.488.95%3.60%
54
Neutral
HK$2.04B3.3911.49%47.32%492.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
25.00
-2.45
-8.93%
LVZPF
Livzon Pharmaceutical Group
3.77
0.29
8.33%
HK:1383
Suncity Group Holdings
SHTDF
Sinopharm Group Co
2.18
-0.72
-24.83%
SHWGF
Shandong Weigao Group Medical Polymer Co
0.75
0.20
36.36%
HK:2198
China Sanjiang Fine Chemicals Co., Ltd.
1.74
0.10
6.10%

Shanghai Kindly Medical Instruments Co., Ltd. Class H Corporate Events

Shanghai INT Medical Instruments Co., Ltd. Announces AGM Results and Board Appointments
May 23, 2025

Shanghai INT Medical Instruments Co., Ltd., a company incorporated in China, held its annual general meeting for 2024 on May 23, 2025. The meeting, chaired by Dr. Liang Dongke, resulted in the approval of all resolutions, including the re-election and appointment of directors and supervisors, and the election of the chairman for the fourth session of the board and supervisory committee. The unanimous approval of the company’s reports and financial statements reflects strong shareholder support and positions the company for continued stability and governance.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments Announces Board Composition
May 23, 2025

Shanghai Kindly Medical Instruments Co., Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement provides clarity on the governance structure of the company, potentially impacting its strategic direction and decision-making processes, which could influence stakeholders’ perspectives on the company’s future operations.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments to Acquire Controlling Stake in Target Company
May 21, 2025

Shanghai Kindly Medical Instruments Co., Ltd., a company incorporated in the People’s Republic of China, has entered into a Formal Acquisition Agreement to acquire a controlling stake in a target company. The acquisition involves purchasing 81.83% equity interest in the target company for approximately RMB512.84 million, with Shanghai Kindly Medical Instruments acquiring a 51.70% controlling stake. This transaction will result in the target company becoming a non-wholly owned subsidiary, and further capital injection is planned. The acquisition is classified as a discloseable transaction under the Listing Rules, requiring reporting and announcement.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments Announces 2025 AGM Agenda
Apr 22, 2025

Shanghai Kindly Medical Instruments Co., Ltd. has announced its upcoming annual general meeting scheduled for May 23, 2025. The meeting will address several resolutions, including the approval of the 2024 financial reports, re-elections of board members, and the appointment of auditors. These decisions are crucial for maintaining the company’s governance and operational continuity.

Shanghai Kindly Medical Instruments Announces Board Re-Elections and Strategic Guarantee Provision
Mar 18, 2025

Shanghai Kindly Medical Instruments Co., Ltd. has announced the proposed re-election and appointment of directors and supervisors for its fourth session of the Board and Supervisory Committee, coinciding with the expiration of the current terms at the upcoming annual general meeting. Additionally, the company has resolved to provide a guarantee to a target company following its acquisition, indicating a strategic move to strengthen its market position and operational capabilities.

Shanghai Kindly Medical Instruments Reports Strong 2024 Financial Results
Mar 18, 2025

Shanghai Kindly Medical Instruments Co., Ltd. reported a significant financial performance for the year ended December 31, 2024, with a 13.17% increase in revenue to RMB851.95 million, driven by heightened market demand and an expanded customer base. The company’s gross profit and profit for the year also saw substantial growth, with gross profit margin rising to 63.11% and profit increasing by 24.03% to RMB190.05 million, reflecting strong operational efficiency and market positioning.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.